Has Christopher Brown, MD received payments from drug or device companies?

Yes. Drug and device makers reported $265,767 in general payments to Christopher Brown, MD across 387 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Christopher Brown, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Christopher Brown, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Christopher Brown, MD

Interventional Cardiology · Seattle, WANPI 1922418789

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (58.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Shockwave Medical, Inc accounts for 84.3% of it on its own, with 19 other manufacturers making up the rest. 2025 is the largest year on record at $95,384, more than ten times the $1,595 reported in 2019. Among interventional cardiology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$265,767in general payments, 2019–2025

Across 387 payments — averaging $686.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Shockwave Medical, Inc$224K
Abiomed$19K
Terumo Medical Corporation$9K
Boston Scientific$5K
Medtronic$4K
Heartflow, Inc.$900
plus $3K from 14 others

$63,026in research payments, 2019–2025

Across 12 payments — averaging $5252.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Shockwave Medical, Inc$62K
Asahi Intecc USA, Inc.$1K

What the payments were for

Consulting fees$154,23858%
Speaking & faculty fees$88,20033%
Travel & lodging$9,4504%
Food & beverage$13,8805%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Shockwave Medical, Inc	109	$224,143
Abiomed	27	$19,112
Terumo Medical Corporation	12	$9,449
Boston Scientific	127	$4,819
Medtronic	32	$4,189
Heartflow, Inc.	2	$900
Cardiovascular Systems Inc.	23	$645
Acist Medical Systems, Inc.	12	$516
Inari Medical, Inc.	9	$404
Biotronik Inc.	10	$321
Stryker	6	$303
Abbott	3	$267
Jenavalve Technology, Inc.	1	$185
Chiesi USA, Inc.	4	$170
Alphatec Spine, Inc	1	$140
Philips North America LLC	2	$67
Asahi Intecc USA, Inc.	3	$55
Masimo Corporation	2	$36
Trevena, Inc.	1	$24
Edwards Lifesciences	1	$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$223,030
Impella$18,505
METACROSS OTW$8,500
COREVALVE EVOLUT R$3,088
FFRct$900
GlideWire$750
AVVIGO Guidance System$583
Vascular Lithotripsy$301
FLOWTRIEVER CATHETER, S$276
CT THROMBECTOMY SYSTEM KIT$276
Diamondback Coronary$234
JenaValve Pericardial TAVR System$185
RESOLUTE ONYX$179
REACTTM$172
STINGRAY$149
POLARIS$148
CVI SYSTEMS$143
GENERAL - THERAPIES$143
Battalion TLIF - PC$140
FlowTriever$135

How this compares

$265,767 in reported general payments places this provider in the 95th percentile of 125 interventional cardiology providers in Washington.

See all interventional cardiology providers in Washington →

Medicare billing

Part B allowed, 2024

$243,884

Medicare patients

403

Services billed

1,493

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	39	$39,291
BrilintaTicagrelor	39	$32,226
Repatha SureclickEvolocumab	12	$9,989
Prasugrel Hcl	47	$2,697
ClopidogrelClopidogrel Bisulfate	264	$2,589
Atorvastatin Calcium	72	$907
Metoprolol Succinate	50	$489
Isosorbide Mononitrate ErIsosorbide Mononitrate	24	$367
Losartan Potassium	33	$340
Carvedilol	30	$294
Rosuvastatin Calcium	20	$257
Amlodipine Besylate	37	$179
Nitroglycerin	17	$169
Lisinopril	32	$142
Furosemide	21	$131

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Seattle

William LombardiSeattle$902K
Kathleen KearneySeattle$448K
Danny DvirSeattle$374K
James McCabeSeattle$289K
Lorenzo AzzaliniSeattle$233K
Sidakpal PanaichSeattle$214K
Christine ChungSeattle$210K
Sameer GafoorSeattle$80K
Ravi HiraSeattle$64K
Ming ZhangSeattle$43K

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →